LB Pharmaceuticals Inc
LBRX
$14.90
-$0.61-3.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.62M | 2.62M | 5.29M | 5.29M | 2.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.29M | 5.29M | 10.81M | 10.81M | 26.58M |
| Operating Income | -5.29M | -5.29M | -10.81M | -10.81M | -26.58M |
| Income Before Tax | -5.09M | -5.09M | -9.63M | -9.63M | -27.70M |
| Income Tax Expenses | -- | -- | 500.00 | 500.00 | -- |
| Earnings from Continuing Operations | -5.09M | -5.09M | -9.63M | -9.63M | -27.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.09M | -5.09M | -9.63M | -9.63M | -27.70M |
| EBIT | -5.29M | -5.29M | -10.81M | -10.81M | -26.58M |
| EBITDA | -5.22M | -5.22M | -10.77M | -10.77M | -26.58M |
| EPS Basic | -20.21 | -20.21 | -38.23 | -38.23 | -64.72 |
| Normalized Basic EPS | -11.91 | -11.91 | -24.97 | -24.97 | -- |
| EPS Diluted | -20.21 | -20.21 | -38.23 | -38.23 | -64.72 |
| Normalized Diluted EPS | -11.91 | -11.91 | -24.97 | -24.97 | -- |
| Average Basic Shares Outstanding | 251.80K | 251.80K | 251.80K | 251.80K | -- |
| Average Diluted Shares Outstanding | 251.80K | 251.80K | 251.80K | 251.80K | 249.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |